Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic The acquisition will result in the business combination of Bone Therapeutics and Medsenic to create BioSenic, a speciality biopharma company51 percent of Medsenic shares (valued at ca EUR 40 million) to.
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces an optimized statistical analysis and the implementation of an interim analysis for the ongoing Phase IIb clinical trial with its allogeneic bone cell .
PRESS RELEASE - INSIDE INFORMATION Recent medical publications provide new insights in timing and dynamics of fracture healing using early radiological.
Bone Therapeutics announces 2021 full year results Strategic focus revised and fully focused on achieving topline results of the ALLOB Phase IIb study in tibial fracturesDiscussions for ALLOB global partnership still ongoingBoard of Directors and Management exploring all strategic options to protect shareholder.
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it is redefining its strategic priorities to concentrate specifically on the development of its most advanced clinical asset, the allogeneic cell therapy .